Organisation

Top Institute Pharma - TI Pharma

Pagina-navigatie:

Main
Current research (38)
Completed research (32)

Current research

(the most recent research is at the top)
Collaboration	Integrative Metabolic Production and Profiling as a Novel Strategy in Hit-to-Lead Selection
Financier	The CSF proteome / metabolome as primary biomarker compartment for CNS disorders
Financier	Rational GPCR compound library design
Financier	Validation of the use of fMRI as an objective measure in pain in patients with and without psychiatric comorbidities
Financier	Modeling of the influence of age-related changes on the pharmacokinetics and pharmacodynamics of drugs; Cytochrome P-450 3A metabolism and GABA A receptor function
Financier	Exploring a novel neuroblastoma therapy: silencing of doublecortin-like, a microtubule-associated protein, using RNA-interferences.
Financier	Identification of psychosis susceptibility genes
Financier	In vivo application of RNA-interference: Targeting doublecortin-like (DCL) in the mouse hippocampus
Financier	Identification of epigenetic changes of glucocorticoid-related pathways shaping susceptibility to stress-related psychiatric disorders
Financier	Anti-psychotic and anti-epileptic drug-induced weight alterations
Secretariat	A versatile lipid based drug delivery system for the treatment of inflammatory diseases and cancer
Secretariat	Optimizing the applicability of stem cell therapy. Improving cord blood stem cell homing and engraftment by liposome-complexed Wnt and molecular imaging
Secretariat	Mechanism-based PK-PD modeling platform
Secretariat	Metabolic stability assessment as a new tool in the Hit-to-Lead selection process and the generation of new lead compound libraries
Secretariat	Exploitation of toll-like receptors in drug discovery
Secretariat	The use of animals in pharmaceuticals Models
Secretariat	CNS drug target validation using RNA interference
Secretariat	Novel susceptibility pathways and drug targets for psychosis
Secretariat	Parkinson and Alzheimer disease: from dysregulated human brain targets towards novel therapeutics
Secretariat	A translational pharmacogenomics approach to improve drug development strategies for psychiatric disorders
Secretariat	Protective human antibodies against multidrug resistant Staphylococcus aureus
Secretariat	Anti-angiogenic miRNA based therapeutics
Secretariat	TNF ligands in cancer
Secretariat	Renin-angiotensin system blockade beyond angiotensin II
Secretariat	Extra pulmonary manifestations and COPD
Secretariat	Target Residence Time
Secretariat	Predicting drug responses in breast cancer
Secretariat	Phosphodiesterase inhibitors for the treatment of Leishmania and Trypanosomiasis
Secretariat	Development and application of novel strategies to induce and monitor humoral and cellular immunity to protect hosts from infection by respiratory viruses
Secretariat	Development of an attenuated parasite vaccine for malaria
Secretariat	Efficient eradication of (multidrug) resistant bacteria
Secretariat	Sustainable orphan drug development through registries and monitoring
Secretariat	The Mondriaan Project: The Dutch healthcare landscape as a 'population laboratory'
Secretariat	Osteoarthritis: models, mechanisms and markers for patient stratification
Secretariat	Advancements in the DESIGN, conduct and analysis of randomised trials on drug effects
Secretariat	The Escher Project : Science driven drug regulation and innovative research throughout phased drug development
Secretariat	Towards novel translational safety biomarkers for adverse drug toxicity
Secretariat	COPD and smoking : Acute and chronic inflammatory response